Xbrane Biopharma Completes State Of The Art Laboratory For Acceleration Of Biosimilar Development

Xbrane has completed the construction of a state of the art laboratory that allows significantly increased capacity and efficiency in the biosimilar development. The laboratory is located in Xbranes new facilities in Hagalunds industrial park in Solna outside Stockholm. The new equipment in combination with several key recruitments of specialists to the team allows Xbrane to accelerate the development of its biosimilars.

"An important milestone for 2016 was to complete the new laboratory. With more bioreactors, from laboratory scale to pilot scale, and state of the art purification equipment we will increase capacity and efficiency in our biosimilar development" says Martin Amark, CEO of Xbrane Biopharma AB.

Xbrane has three biosimilars under development. Xlucane is a Ranibizumab biosimilar for treatment of age related macula degeneration. Xcimzane is a biosimilar on the originator drug Cimzia used in treatment of rheumatoid arthritis and Xoncane is a biosimilar on Oncaspar used in treatment of acute lymphoblastic leukaemia. The biosimilar portfolio addresses a market where the originator drugs has a combined turnover of 45 BSEK.

Xbranes new address is Banvaktsvagen 22, 171 48 Solna, Sweden.

About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in High Demand Complex Generics. Xbrane has world leading expertise in developing generics for injectable controlled release drugs and proprietary high yield protein expression technology for the development of biosimilars. The goal is to become a global leader within the companys portfolio of High Demand Complex Generics. Xbranes's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd under the name XBRANE and Avanza Bank AB is Xbranes certified advisor. For more information see www.xbrane.com.

© Copyright 2016, GlobeNewswire, Inc. All Rights Reserved.